FindTrial
Sign In

Omalizumab treatment in patients with antihistamines-refractory chronic urticaria: a real-world study in China

Omalizumab treatment in patients with antihistamines-refractory chronic urticaria: a real-world study in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038085
Enrollment
Unknown
Registered
2020-09-10
Start date
2019-02-01
Completion date
Unknown
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic urticaria

Interventions

Case series:omalizumab

Sponsors

Department of Dermatology and Venereology, Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Fullfilled the diagnostic criteria of chronic spontaneous urticaria and/or chronic inducible urticaria; 2. Had received >= 3 treatments with omalizumab and >=3 follow-up visits.

Exclusion criteria

Exclusion criteria: Patients who were participating in the clinical trial of omalizumab were not included.

Design outcomes

Primary

MeasureTime frame
urticaria activity score;—

Secondary

MeasureTime frame
urticaria control test;chronic urticaria quality-of-life questionnaire;dermatology life quality index;—

Countries

China

Contacts

Public ContactZhao Zuotao

Peking University First Hospital

zhaozuotaotao@163.com+86 15210468333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026